Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis

Prostate

Volumn 68, Issue 3, 2008, Pages 321-335

  Narita, Shintaro ^a   Tsuchiya, Norihiko ^a   Saito, Mitsuru ^a   Inoue, Takamitsu ^a   Kumazawa, Teruaki ^a   Yuasa, Takeshi ^a   Nakamura, Akira ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

High fat diet; Insulin like growth factor I receptor; Microarray; Prostate cancer

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BODY MASS; CANCER GROWTH; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPID DIET; LOW FAT DIET; MALE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; TUMOR XENOGRAFT; UNINDEXED SEQUENCE; UPREGULATION;

ANIMALS; DIETARY FATS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 39449083288     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20681     Document Type: Article

References (44)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30.
2. Watanabe M, Nakayama T, Shiraishi T, Stemmermann GN, Yatani R. Comparative studies of prostate cancer in Japan versus the United States. A review. Urol Oncol 2000;5(6):274-283.
3. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977;20(5):680-688.
4. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63(6):963-966.
5. Wakai K. Descriptive epidemiology of prostate cancer in Japan and Western countries. Nippon Rinsho 2005;63(2):207-212.
6. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll PR. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005;174(3):1065-1069, discussion 1069-1070.
7. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993;85(19):1571-1579.
8. Fair WR, Fleshner NE, Heston W. Cancer of the prostate: A nutritional disease? Urology 1997;50(6):840-848.
9. Connolly JM, Coleman M, Rose DP. Effects of dietary fatty acids on DU145 human prostate cancer cell growth in athymic nude mice. Nutr Cancer 1997;29(2):114-119.
10. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 1995;87(19): 1456-1462.
11. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23(32): 8152-8160.
12. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, deGregorio F, Elshimali YI, Heber D, Aronson WJ. Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clin Cancer Res 2003;9(7):2734-2743.
13. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-1818.
14. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51(14):3753-3761.
15. Liao Y, Abel U, Grobholz R, Hermani A, Trejan L, Angel P, Mayer D. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol 2005;36(11):1186-1196.
16. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-1 and prostate cancer risk: A prospective study. Science 1998;279(5350):563-566.
17. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor 1 (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001;61(16):6276-6280.
18. Bray GA, Popkin BM. Dietary fat intake does affect obesity! Am J Clin Nutr 1998;68(6):1157-1173.
19. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75(8):1111-1118.
20. Clemmons DR, Klibanski A, Underwood LE, McArthur JW, Ridgway EC, Beitins IZ, Van Wyk JJ. Reduction of plasma immunoreactive somatomedin C during fasting in humans. J Clin Endocrinol Metab 1981;53(6):1247-1250.
21. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Koumantaki Y, Mantzoros CS. Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J Clin Oncol 1999;17(10)3291-3298.
22. Phillips LS, Harp JB, Goldstein S, Klein J, Pao CI. Regulation and action of insulin-like growth factors at the cellular level. Proc Nutr Soc 1990;49(3):451-458.
23. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinohara T, Hinuma S, Fujisawa Y, Fujino M. Free fatty acids regulate insulin secretion from pancreatic beta cells through G PR40. Nature 2003;422(6928):173-176.
24. Askari B, Carroll MA, Capparelli M, Kramer F, Gerrity RG, Bornfeldt KE. Oleate and linoleate enhance the growth-promoting effects of insulin-like growth factor-I through a phospholipase D-dependent pathway in arterial smooth muscle cells. J Biol Chem 2002;277(39):36338-36344.
25. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002;43(1):1-8.
26. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: Association with an aggressive phenotype. Cancer Res 1999;59(15): 3588-3591.
27. Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V. Insulin-like growth factor (IGF)-I, IGF-II and IGE type 1 receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003;23(5A):3825-3835.
28. Burfeind P, Chernicky CL, Rininsland F, Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996;93(14):7263-7268.
29. Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Burfeind P. Blockade of the type IIGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. J Pathol 2004;202(1):50-59.
30. Zhu Z, Jiang W, Thompson HJ. Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: In vivo effects of corticosterone on cell cycle machinery in mammary carcinomas. Carcinogenesis 2003;24(7):1225-1231.
31. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, Belfiore A. Androgens up-regulate the insulin-like growth factor-1 receptor in prostate cancer cells. Cancer Res 2005;65(5): 1849-1857.
32. Volek JS, Gomez AL, Love DM, Avery NG, Sharman MJ, Kraemer WJ. Effects of a high-fat diet on postabsorptive and postprandial testosterone responses to a fat-rich meal. Metabolism 2001;50(11):1351-1355.
33. Voskuil DW, Vrieling A, van't Veer LJ, Kampman E, Rookus MA. The insulin-like growth factor system in cancer prevention: Potential of dietary intervention strategies. Cancer Epidemiol Biomarkers Prev 2005;14(1):195-203.
34. Bahr C, Groner B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 2005;23(1):1-14.
35. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki Y, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Garcia-Echeverria C, Pearson MA, Hofmann F, Anderson KC, Kung AL. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5(3):221-230.
36. Martins AS, Mackintosh C, Martin DH, Campos M, Hernandez T, Ordonez JL, de Alava E. Insulin-like growth factor 1 receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin,or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12(11 Pt 1):3532-3540.
37. Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, Yamamoto N, Okano H, Sugimoto K, Murata K, Nakano T. Functional expression of TWEAK in human hepatocellular carcinoma: Possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun 2004;318(3):726-733.
38. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005;280(5):3483-3492.
39. Shimada M, Shimano H, Gotoda T, Yamamoto K, Kawamura M, Inaba T, Yazaki Y, Yamada N. Overexpression of human lipoprotein lipase in transgenic mice. Resistance to diet-induced hypertriglyceridemia and hypercholesterolemia. J Biol Chem 1994;269(15):11673.
40. Narita S, Tsuchiya N, Wang L, Matsuura S, Ohyama C, Satoh S, Sato K, Ogawa O, Habuchi T, Kato T. Association of lipoprotein lipase gene polymorphism with risk of prostate cancer in a Japanese population. Int J Cancer 2004;112(5):872-876.
41. Nomura K, Noguchi Y, Yoshikawa T, Kondo J. Plasma interleukin-6 is not a mediator of changes in lipoprotein lipase activity in cancer patients. Hepatogastroenterology 1997;44(17): 1519-1526.
42. Nara-Ashizawa N, Akiyama Y, Maruyama K, Tsukada T, Yamaguchi K. Lipolytic and lipoprotein lipase (LPL)-inhibiting activities produced by a human lung cancer cell line responsible for cachexia induction. Anticancer Res 2001;21(5):3381-3387.
43. Hozumi Y, Kawano M, Hakamata Y, Miyata M, Jordan VC. Tamoxifen inhibits lipoprotein activity: In vivo and in vitro studies. Horm Res 2000;53(1):36-39.
44. Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 2006;66(9): 4602-4609.